Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00729001
Other study ID # 444563/005
Secondary ID
Status Completed
Phase Phase 2
First received August 4, 2008
Last updated September 15, 2016
Start date November 2000
Est. completion date September 2002

Study information

Verified date September 2016
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a dose exploration study to assess the safety and immunogenicity of two doses of the candidate HRV vaccine at different virus concentrations in the target age group (infants approximately 2 months of age and previously uninfected with human rotavirus) and receiving concomitant administration of routine vaccinations. The study also aims at exploring the effect of unrestricted feeding on the immunogenicity of the vaccine.


Description:

All subjects enrolled from Eastern United States and Eastern Canada will continue their participation in the pilot efficacy follow-up (pilot efficacy subset).

The third dose of IPV vaccine (IPOL) may be given at visit 3, 4 or another time, at the investigator's discretion.

Comvax may be given in place of OmniHIB/ActHIB at Visit 1 and Visit 2 and the third dose of Comvax administered according to the prescribing information.


Recruitment information / eligibility

Status Completed
Enrollment 529
Est. completion date September 2002
Est. primary completion date September 2002
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria:

- A male or female child between, and including 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.

- Free of obvious health problems as established by medical history and clinical examination before entering into the study.

- Written informed consent obtained from the parents or guardians of the subject.

- Born after a normal gestation period (between 36 and 42 weeks).

Exclusion Criteria:

- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine or placebo or planned use during the study period.

- Planned administration of a vaccine (including routine pediatric vaccines) not foreseen by the study protocol during the period starting from 14 days before each dose of vaccine(s) and ending 14 days after. Hepatitis B vaccine given concomitantly or within 14 days before and after vaccination is not an exclusion criteria.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.

- History of diphtheria, tetanus, pertussis, polio, Hib disease and/or invasive pneumococcal infection. History of invasive pneumococcal infection is not an exclusion criteria for Canadian subjects.

- Previous vaccination against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and/or Streptococcus pneumoniae. Previous vaccination against Streptococcus pneumoniae is not an exclusion criteria for Canadian subjects.

- Use of antibiotics within 7 days preceding dose 1.

- Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

- History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.

- Acute disease at time of enrollment.

- Gastroenteritis within 7 days preceding the study vaccine administration.

- Household contact with an immunosuppressed individual or pregnant women.

- Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.

- Previous confirmed occurrence of rotavirus gastroenteritis.

- Inability to contact parents/guardians of the subject by telephone.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Human Rotavirus Vaccine - two different formulations
Two oral doses
Prevnar
Three-dose intramuscular injection (US subjects only)
IPOL
Two-dose intramuscular injection (US subjects only)
Infanrix
Three-dose intramuscular injection (US subjects only)
OmniHIB
Three-dose intramuscular injection (US subjects only)
Pentacel
Three-dose intramuscular injection (Canada only)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

References & Publications (2)

Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH Jr, Innis BL, Rathfon H, Schuind A, De Vos B; North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J. 2005 Jun;24(6):481-8. — View Citation

Dennehy PH; North American Human Rotavirus Vaccine Study Group. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine. 2006 May 1;24(18):3780-1. Epub 2005 Aug 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with vaccine take Two months after the second dose
Primary Occurrence of any grade 2 or 3 fever, vomiting or diarrhea Within the 15-day solicited follow-up period after any dose of study vaccine.
Secondary Occurrence of each type of solicited symptoms Within the 15-day solicited follow-up period after any dose of study vaccine
Secondary Occurrence of unsolicited symptoms according to WHO classification. Within 42 days after dose 1 and dose 2
Secondary Occurrence of serious adverse events Throughout the entire study period
Secondary Serum rotavirus immunoglobulin A (IgA) antibody titers At visits 1, 3 and 4 and at all Visits for pilot efficacy subset
Secondary Rotavirus seropositivity status Before dose 1 and at the end of the study
Secondary Vaccine take (for pilot efficacy subset only) 2 months after dose 1
Secondary Anti- polyribosyl-ribitol phosphate (PRP), anti-diphtheria and anti-tetanus toxoids, anti- pertussis toxoid (PT), anti- filamentous haemagglutinin (FHA), anti- pertactin (PRN), anti-polio type 1, 2 and 3 antibody concentrations Two months after dose 2 and at the end of the study.
Secondary Antibody concentrations to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Two months after dose 2 and at the end of the study (only in a subset of U.S. subjects)
Secondary Anti-PRP, anti-diphtheria, anti-tetanus, anti-polio type 1, 2 and 3 seroprotection status. Two months after dose 2 and at the end of the study.
Secondary Anti-PT, anti-FHA, anti-PRN, pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (only in US subjects) seropositivity status. Two months after dose 2 and at the end of the study.
Secondary Seropositivity status and Geometric mean titres (GMTs) of rotavirus IgA for breast fed infants compared with formula fed infants Two months after dose 2.
Secondary Occurrence of rotavirus gastroenteritis (in a pilot efficacy subset of subjects) Two weeks after dose 2 until the end of the rotavirus season following vaccination.
See also
  Status Clinical Trial Phase
Completed NCT01435967 - Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ N/A
Completed NCT00370318 - Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines Phase 3
Completed NCT00345956 - To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) Phase 3
Completed NCT00140686 - To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines Phase 3
Completed NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa Phase 2
Completed NCT00750893 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
Completed NCT00533507 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Phase 3
Completed NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) Phase 3
Completed NCT02914184 - Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks Phase 3
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00779779 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
Completed NCT00382772 - A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). Phase 3
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Completed NCT01198769 - Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. Phase 4
Completed NCT00385320 - Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months Phase 2
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT01563159 - Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 N/A
Completed NCT01339221 - Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium N/A
Completed NCT00653198 - Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama N/A